Form 4: Allogene CFO's Equity Transactions Revealed

Allogene Therapeutics' CFO, Geoffrey M. Parker, reported a 'sell to cover' stock sale and new equity awards, including stock options and restricted stock units.

Summary

• Chief Financial Officer Geoffrey M. Parker reported equity transactions on February 2, 2026.
• Sold 24,001 shares of Allogene Therapeutics Common Stock at a weighted average price of $1.76 per share.
• The sale was a non-discretionary 'sell to cover' transaction to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Received a grant of 539,072 stock options with an exercise price of $1.87 per share, expiring on February 2, 2036.
• The stock options will vest 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
• Received an award of 152,480 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock.
• The RSUs will vest in four successive equal annual installments over a four-year period from February 2, 2026, subject to continued service.
• Following these transactions, Mr. Parker beneficially owns 1,252,795 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, primarily reflecting routine executive compensation and tax-related transactions rather than new operational or financial performance insights.

Positives

• Grant of 539,072 stock options to the CFO, aligning long-term incentives.
• Award of 152,480 Restricted Stock Units (RSUs) to the CFO, further aligning executive interests with shareholder value.

Negatives

• Sale of 24,001 shares of common stock by the CFO, although it was a non-discretionary 'sell to cover' for tax purposes.

Future Outlook

The vesting schedules for the granted stock options and Restricted Stock Units (RSUs) extend several years into the future, contingent on the CFO's continued service, indicating a long-term incentive structure.

Industry Context

StockSavvy.ai notes that the grant of stock options and restricted stock units to a Chief Financial Officer is a standard practice in the biotechnology industry for executive compensation, aligning management incentives with long-term shareholder value. The 'sell to cover' transaction is also a common mechanism for executives to meet tax obligations upon RSU vesting without engaging in discretionary sales.

Comparison to Industry Standards

• Executive compensation packages, including equity grants like stock options and RSUs, are standard across the biotechnology sector.
• While specific grant sizes vary based on company size, performance, and executive role, the structure observed here is consistent with typical industry practices for retaining and incentivizing key leadership.

Stakeholder Impact

• Shareholders: Minor dilution from new equity grants, but the grants align the CFO's incentives with long-term shareholder value.
• Employees: No direct impact on the broader employee base is mentioned in this filing.

Next Steps

• 25% of the granted stock options will vest on February 2, 2027, with the remaining vesting in 36 equal monthly installments thereafter.
• The awarded Restricted Stock Units (RSUs) will vest in four successive equal annual installments over a four-year period from February 2, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants and a non-discretionary 'sell to cover' transaction for tax purposes. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing does not alter the existing investment thesis.

Keywords

Allogene Therapeutics, ALLO, Form 4, Insider Transaction, CFO, Equity Compensation, Stock Options, Restricted Stock Units, Sell to Cover